A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

Proceedings of the National Academy of Sciences of the United States of America

Volumn 103, Issue 40, 2006, Pages 14901-14906

  Whitnall, Megan ^a   Howard, Jonathan ^a   Ponka, Prem ^b   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; di 2 pyridylketone 4,4 dimethyl 3 thiosemicarbazone; Ndrg1

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; BETA ACTIN; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE ISONICOTINOYLHYDRAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE; ETOPOSIDE; IRON CHELATING AGENT; ISONIAZID DERIVATIVE; PROTEIN; PROTEIN NDRG1; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE; GENE CONTROL; HUMAN; HUMAN CELL; IRON CHELATION; MOUSE; NDRG1 GENE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHELATION THERAPY; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MICE; MICE, NUDE; MYOCARDIUM; NEOPLASMS; ORGAN SIZE; PYRIDINES; SPLEEN; THIOSEMICARBAZONES; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS;

EID: 33749515083     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0604979103     Document Type: Article

References (40)

1. Le NT, Richardson DR (2002) Biochim Biophys Acta 1603:31-46.
2. Buss JL, Greene BT, Turner J, Torti FM, Torti SV (2004) Curr Top Med Chem 4:1623-1635.
3. Kalinowski DS, Richardson DR (2005) Pharmacol Rev 57:547-583.
4. Thelander L, Reichard P (1979) Annu Rev Biochem 48:133-158.
5. Richardson DR, Milnes K (1997) Blood 89:3025-3038.
6. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, Gelfand E, Seligman P (1993) Cancer Res 53:3968-3975.
7. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Biochem Pharmacol 59:983-991.
8. Ponka P, Borova J, Neuwirt J, Fuchs O (1979) FEBS Lett 97:317-321.
9. Richardson DR, Tran EH, Ponka P (1995) Blood 86:4295-4306.
10. Yuan J, Lovejoy DB, Richardson DR (2004) Blood 104:1450-1458.
11. Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR (2003) Br J Pharmacol 138:819-830.
12. Le NT, Richardson DR (2004) Blood 104:2967-2975.
13. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, Watabe K (2003) Cancer Res 63:1731-1736.
14. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Cancer Res 58:4439-4444.
15. Aouali N, Eddabra L, Macadre J, Morjani H (2005) Crit Rev Oncol Hematol 56:61-70.
16. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Cancer Res 54:152-158.
17. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Somat Cell Mol Genet 11:117-126.
18. Shen DW, Cardarelli C, Hwang J, Cornwell M, Riehen N, Ishii S, Pastan I, Gottesman MM (1986) J Biol Chem 261:7762-7770.
19. Abeysinghe RD, Greene BT, Haynes R, Willingham MC, Turner J, Planalp RP, Brechbiel MW, Torti FM, Torti SV (2001) Carcinogenesis 22:1607-1614.
20. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, et al. (1997) Cancer Res 57:4285-4300.
21. Lowe SW (1995) Curr Opin Oncol 7:547-553.
22. Guimaraes DP, Hainaut P (2002) Biochimie 84:83-93.
23. Richardson DR (2005) Curr Med Chem 12:2711-2729.
24. Park JH, Kim TY, Jong HS, Chun YS, Park JW, Lee CT, Jung HC, Kim NK, Bang YJ (2003) Clin Cancer Res 9:433-440.
25. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT (2000) J Biol Chem 275:25130-8.
26. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, Bernhardt PV (2006) J Med Chem, in press.
27. Chaston TB, Watts RN, Yuan J, Richardson DR (2004) Clin Cancer Res 10:7365-7374.
28. Bernhardt PV, Caldwell LM, Chaston TB, Chin P, Richardson DR (2003) J Biol Inorg Chem 8:866-880.
29. Richardson DR, Bernhardt PV (1999) J Biol Inorg Chem 4:266-273.
30. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Cancer Res 65:6943-6949.
31. Jiang ZG, Lu XC, Nelson V, Yang X, Pan W, Chen RW, Lebowitz MS, Almassian B, Tortella FC, Brady RO, Ghanbari HA (2006) Proc Natl Acad Sci USA 103:1581-1586.
32. Xu X, Persson HL, Richardson DR (2005) Mol Pharmacol 68:261-271.
33. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E (2003) Cardiovasc Toxicol 3:89-99.
34. Saad SY, Najjar TA, Al-Rikabi AC (2001) Pharmacol Res 43:211-218.
35. Linden T, Wenger RH (2003) Int J Cancer 106:458-459.
36. Green DA, Antholine WE, Wong SJ, Richardson DR, Chitambar CR (2001) Clin Cancer Res 7:3574-3579.
37. Chong TW, Horwitz LD, Moore JW, Sowter HM, Harris AL (2002) Cancer Res 62:6924-6927.
38. Gao J, Richardson DR (2001) Blood 98:842-850.
39. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Menard S, Pratesi G (2004) Eur J Cancer 40:1275-1281.
40. Dunn LL, Sekyere EO, Rahmanto YS, Richardson DR (May 16, 2006) Carcinogenesis, 10.1093/carcin/bgl045.